RenovoRx enrolls first patient in PRISM‑TAMP investigator‑initiated trial for borderline pancreatic cancer
RenovoRx announced that the University of Vermont‑sponsored PRISM‑TAMP trial has enrolled its first patient. The study evaluates gemcitabine delivered via the company’s TAMP platform and RenovoCath device in about ten patients with borderline resectable pancreatic ductal adenocarcinoma. The trial follows the company’s Phase III TIGeR‑PaC study, which completed enrollment in August 2026. RenovoRx reported $1.1 million in RenovoCath sales for 2025 and $909 000 in Q2 2026.
Why it matters
The enrollment demonstrates clinical progress for RenovoRx’s TAMP technology, which could generate safety and efficacy data that may support future regulatory filings. The company expects topline data from its Phase III TIGeR‑PaC trial in the second half of 2027, and data from PRISM‑TAMP could further inform the product’s market potential.
Key facts
- 1The first patient was enrolled in the PRISM‑TAMP trial on Oct. 7 2026. globenewswire.com
- 2The University of Vermont plans to enroll approximately 10 patients in the study (NCT07477418). globenewswire.com
- 3RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025. globenewswire.com
- 4RenovoRx recorded $909,000 in RenovoCath revenue in Q2 2026. globenewswire.com
- 5RenovoRx expects topline data from its Phase III TIGeR‑PaC trial in the second half of 2027. globenewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.